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ABSTRACT
Acute Escherichia coli mastitis is one of the major
sources of economic loss in the dairy industry due to
reduced milk production, treatment costs, discarded
milk, and occasional fatal disease. Nonsteroidal anti-
inflammatory drugs (NSAIDs) are frequently used as
adjunctive therapy to antibiotics. The objective of the
current study was to evaluate the effect of carprofen
treatment following infusion of Escherichia coli into
the mammary glands of primiparous cows during the
periparturient period. Severity of mastitis was scored
based on the average milk production in the uninfected
quarters on d +2 postinoculation and a clinical severity
score. Carprofen was administered intravenously at 9
h postchallenge, when clinical signs of mastitis ap-
peared. In previous work, efficacy of NSAIDs was
mainly evaluated using clinical symptoms. In the pres-
ent study, the effect of carprofen on innate immune
response was also assessed by quantification of in-
flammatory mediators. All primiparous cows reacted
as moderate responders throughout the experimental
period. Primiparous cows were intramammarily inocu-
lated with 1 × 104 cfu ofE. coliP4:O32 in 2 left quarters.
Analysis of blood and milk parameters, including IL-8,
complement component C5a, lipopolysaccharide-bind-
ing protein (LBP), soluble CD14, prostaglandin E2, and
thromboxane B2 was performed from d 0 to d +6 relative
to intramammary inoculation. Rectal temperature in
carprofen-treated animals was lower than in control
animals at 3 and 6 h posttreatment. Treatment also
restored the decreased reticulorumen motility that oc-
curs during E. colimastitis to preinfection levels faster
than in control animals. Carprofen treatment resulted
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in an earlier normalization of the clinical severity score.
Eicosanoid (prostaglandin E2 and thromboxane B2) pro-
duction in milk tended to be inhibited by carprofen. No
significant differences in the kinetic patterns of somatic
cell count, IL-8, complement component C5a, LBP, and
soluble CD14 were observed. In conclusion, carprofen
treatment improved general clinical condition by effec-
tive antipyrexia and restoration of reticulorumenmotil-
ity but did not significantly inhibit eicosanoid produc-
tion. Carprofen treatment did not result in a significant
decrease of chemotactic inflammatory mediators, IL-8
and C5a, and early innate immune molecules, sCD14
and LBP. Therefore, major modulatory effects from
NSAID administration were not observed in this masti-
tis model, although a larger study might confirm some
apparent trends obtained in the present results.
(Key words: primiparous cow, carprofen, Escherichia
coli mastitis, moderate inflammation)
Abbreviation key: C5a = complement component 5a,
COX = cyclo-oxygenase, HR = heart rate, LBP = LPS-
binding protein, NSAID = nonsteroidal anti-inflam-
matory drug,PGE2= prostaglandinE2,PIH= postinfu-
sion hour, RT = rectal temperature, sCD14 = soluble
CD14, TMB = tetramethylbenzidine, TXB2 = throm-
boxane B2.
INTRODUCTION
Production costs attributed to mastitis represent one
of the largest economic losses to the dairy industry.
Mastitis caused by coliform bacteria is responsible for
a major portion of these losses, predominantly as the
result of acute clinical disease, and is associated with
animal welfare problems related to significant clinical
severity, toxemia, pain, and occasional mortality. Coli-
formmastitis in cattle may be associated with systemic
clinical disease, which occurs predominantly in the pe-
riod immediately after calving (Hill, 1981; Wilesmith
et al., 1986; Burvenich et al., 2003). Systemic signs
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include general depression, fever, tachycardia, inhibi-
tion of reticulorumen motility, and many nonspecific
responses, such as neutropenia, followed by leucocyto-
sis (Verheijden et al., 1983). Considerable losses inmilk
production may occur in cows suffering from Esche-
richia coli mastitis (Hill, 1981; Lohuis et al., 1989; Do-
sogne et al., 1997; Hoeben et al., 2000). Inhibition of
reticulorumen motility is a frequent consequence of E.
coli mastitis (Verheijden et al., 1983) and results in
perturbation of microbial degradation of ingested feed
andmay contribute to decreasedmilk production.More-
over, the marked decreases in plasma tyrosine levels
that occur (Vandeputte-Van Messom et al., 1987) are
not directly related to peak fever.
The pathophysiology of E. coli mastitis is character-
ized by the presence of endotoxin or LPS in the outer
membrane of the etiological bacteria. Lipopolysaccha-
ride is a proinflammatorymolecule that is shed from the
bacterial surface during bacterial replication or death
(Burvenich et al., 2003). Clinical signs following experi-
mentally induced E. coli mastitis are attributed to me-
diator shock rather than to endotoxin shock, because
endotoxinmainly plays a local role (Hoeben et al., 2000;
Dosogne et al., 2002). Several of the proinflammatory
cytokines that mediate the localized and systemic re-
sponse to gram-negative mastitis, including IL-1β, IL-
6, IL-8, and tumor-necrosis factor-α, are upregulated by
LPS (Shuster et al., 1993; Guha and Mackman, 2001).
Binding of LPS to cell membranes also activates the
membrane-bound enzyme, phospholipase A2, liberat-
ing arachidonic acid, which can be metabolized by 2
major enzyme systems, cyclo-oxygenase (COX) and li-
poxygenase. The prostaglandins, prostacyclin and
thromboxanes, are the products of the COX pathway,
whereas the leukotrienes are synthesized following li-
poxygenase enzyme activity. The eicosanoids are im-
portantmediators andmodulators of inflammation, and
play a role in the mediation of acute inflammation (An-
derson, 1989;Rose et al., 1989). Intracerebroventricular
injection of 50 to 200 µg of prostaglandin E2 (PGE2) in
lactating goats elicited fever in normal lactating goats,
the rise and fall being accompanied respectively by a
decrease and an increase of mammary blood flow (Bur-
venich et al., 1982). Pretreatment with flurbiprofen (ad-
ministered intracerebroventricularly) inhibited fever
and changes in heart rate (HR) following experimen-
tally induced LPS mastitis, but had little effect on the
Cl− concentration in the affected mammary gland. Nev-
ertheless, the first peak in the mammary blood flow
curve occurred with some delay, whereas the second
peak was clearly decreased (Burvenich, 1985). Intrave-
nous pretreatment with flurbiprofen abolished fever
and delayed the changes inmilk ion concentration (Bur-
venich et al., 1989). It has also been shown that the
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release of plasma cortisol after intravenous LPS admin-
istration is partially controlled by prostaglandins (Mas-
sart-Lee¨n et al., 1992).
Nonsteroidal anti-inflammatory drugs (NSAID) with
antipyretic, analgesic, and anti-inflammatory activi-
ties, have been used as adjunctive or alternative ther-
apy to systemic or intramammary antibiotics (Shpigel
et al., 1994). Nonsteroidal anti-inflammatory drugs
have been reported to alter the clinical course of E. coli
or endotoxin-induced mastitis in the bovine. A distinct
difference has to be made between their potential anti-
pyretic and antiphlogistic activities. Various NSAIDs
have different physicochemical characteristics, which
result in unequal tissue distribution throughout the
body and cause variations in pharmacokinetics, effi-
cacy, and toxicity among species (Brune, 1990). In addi-
tion, the mechanism of action of NSAIDs may vary by
selective inhibition of the synthesis of a particular class
of prostaglandins and endoperoxides and by inhibition
of biochemical reactions, in addition to COX inhibition
(Kopcha and Ahl, 1989; Kopcha et al., 1992).
Cyclo-oxygenase has 2 isoforms, COX-1, which is con-
stitutively expressed in most tissues and is responsible
for maintenance of various physiological processes,
such as normal body temperature; and inducible COX-
2, a proinflammatory enzyme. Induction of COX-2 syn-
thesis is stimulated by several cytokines (IL-1, tumor-
necrosis factor-α), growth factors, and LPS (Lees et
al., 2000). Most veterinary NSAIDs in current use are
nonselective COX-1 and COX-2 inhibitors. It was re-
cently demonstrated in a rat model of inflammation
that the acute early peak expression of COX-2, which
was proinflammatory, was followed by a second, larger
increase of COX-2 expression, being anti-inflammatory
(Gilroy et al., 1999). There is considerable interest in
the development of specific COX-2 inhibitors for thera-
peutic use. However, interspecies variability in COX
selectivity with regard to veterinary medicine can be
enormous. The COX antagonists currently used in vet-
erinary medicine are all regarded as nonspecific inhibi-
tors of COX-1 and 2, with similar potencies against both
enzymes, or even some selectivity for COX-1 inhibition
(Lees et al., 2000). Until now, COX selectivity of carpro-
fen in cattle remains unknown. However, in other spe-
cies, carprofen COX selectivity was quite variable, from
COX-1 specific in man, nonspecific in horses, and COX-
2 specific in dogs (Brideau et al., 2001).
The effects of NSAIDs have been studied in experi-
mental coliform- and endotoxin-induced mastitis mod-
els. The NSAIDs have included flunixin meglumine
(Anderson et al., 1986; Anderson, 1989; Lohuis et al.,
1989), carprofen (Lohuis et al., 1991), flurbiprofen (Bur-
venich and Peeters, 1982; Vandeputte-Van Messom et
al., 1987; Burvenich et al., 1989; Lohuis et al., 1989),
CARPROFEN TREATMENT FOLLOWING E. COLI MASTITIS 2363
ketoprofen (Ziv and Longo, 1991), ibuprofen (DeGraves
and Anderson, 1993), indomethacine (Burvenich and
Peeters, 1982), suprofen (Burvenich and Peeters, 1982),
and meloxicam (Banting et al., 2000). In these studies,
NSAIDs positively affected various clinical, hematolog-
ical, biochemical, and pathophysiological parameters.
Recently, ketoprofen, phenylbutazone, and dipyrone
were shown to have beneficial effects in the treatment
of field cases of clinical mastitis (Shpigel et al., 1994,
1996). However, these beneficial effects were claimed
using NSAID treatment against a historical control
group, which could raise questions with respect to a
possible confusion between treatment effects and tem-
poral effects. All NSAIDs in these studies were used as
adjunctive therapy in combinationwith the administra-
tion of a systemic antibiotic, trimethoprim sulfonamide.
Carprofen [(±)-6-chloro-α-methylcarbazole-2-acetic
acid] is an NSAID that is well tolerated in the bovine
(Ludwig et al., 1989). In healthy cows, carprofen is phar-
macokinetically characterized by a small distribution
volume (0.09 L/kg), a relatively low systemic clearance
(2.4 mL/h per kg), and a long terminal half-life (30.7
h) (Lohuis et al., 1991). During an endotoxin-induced
mastitic episode, systemic clearance decreased,
whereas terminal half-life significantly increased (43.0
h). Following carprofen treatment at 2 h postchallenge,
a significant reduction in severity of clinical parameters
was observed.
A role for soluble CD14 (sCD14) and LPS-binding
protein (LBP) in mediating bovine host responses to
intramammary LPS or E. coli challenge has recently
been demonstrated (Wang et al., 2002; Bannerman et
al., 2003; Lee et al., 2003a,b). Following intramammary
LPS infusion, sCD14 increases in milk (Bannerman et
al., 2003; Lee et al., 2003a), paralleled by an increase
in LBP (Bannerman et al., 2003). Moreover, sCD14 has
been shown to sensitize the mammary gland to LPS
(Wang et al., 2002) and to reduce the severity of experi-
mental E. coli mastitis in mice (Lee et al., 2003c) and
cows (Lee et al., 2003b). Interestingly, maximal levels
of the chemoattractant IL-8 and complement compo-
nent 5a (C5a) were observed before increases in either
milk LBP or sCD14. This suggests that initial host cell
activation can occur in the presence of basal levels of
sCD14 and LBP (Bannerman et al., 2003; Vangroen-
weghe et al., 2004b). Furthermore, PMNL influx (as
determined by SCC) occurred before increases in sCD14
and LBP, indicating that heightened levels of these
molecules were not required for immediate host innate
immune responses (Bannerman et al., 2003; Vangroen-
weghe et al., 2004b).
Until now, the few reports on the treatment of experi-
mentally induced E. coli mastitis with NSAID have
focused on the effects of these drugs on clinical symp-
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toms rather than biochemical parameters and eicosa-
noids. The objective of the present studywas to examine
the modulatory effect of carprofen treatment on differ-
ent clinical, blood, and milk parameters following mod-
erate inflammation in primiparous cows.
MATERIALS AND METHODS
Experimental Animals and Study Facilities
Experimental infections were approved by the Ethi-
cal Committee of the Faculty of Veterinary Medicine
(Ghent University, Merelbeke, Belgium). The experi-
mental infection was performed in a 2-mo period during
spring, from April to June 2004. The study was con-
ducted to good clinical practice standards under veteri-
nary supervision and complied with applicable animal
welfare and regulatory requirements. Provision for
withdrawal of animalswas based on predefined severity
criteria. The treatmentwas blindedwith respect to clin-
ical observations and laboratory analyses. All primipa-
rous cows (n = 25)were between 24 and30moat calving.
Cows arrived at the commercial dairy farm (Oude-
naarde, Belgium) within 7 d after calving. The animals
were on a system of zero grazing from arrival until the
end of the inoculation trial and were fed twice daily at
0700 and 1700 h. The ration consisted of corn silage,
good quality hay, and water ad libitum. Concentrates
(Sandilac; Dumoulin Voeders Sanders, Moorslede, Bel-
gium) were distributed according to milk production.
Animals treated within 10 d before the intramam-
mary inoculation were not included in the trial. There-
fore, only healthy animals, free of majormastitis patho-
gens through 3 consecutive bacteriologically negative
examinations, and with milk SCC below 100,000 cells/
mL on quarter basis were included for the intramam-
mary E. coli challenge. Primiparous cows accepted for
the intramammary challenge were inoculated between
12 and 28 d postparturition.
Milking was performed daily at 0800 and 1800 h
using a quarter milking device (Packo and Fullwood,
Zedelgem, Belgium). Daily quartermilk production, the
yield of the evening and subsequent morning milking
(expressed as L/d) was measured at d −7, −4, −1, 0,
[postinfusion hour (PIH) 0 to 24], d 1 (PIH 24 to 48),
d 2 (PIH 48 to 72), d 3 (PIH 72 to 96), and d 6 (PIH
144 to 168).
Inoculation Dose
The generation time ofE. coli inmammary secretions
can be as short as 20 min (Petsch and Anspach, 2000;
Burvenich et al., 2003). The primiparous cows were




Inoculation was performed as described previously
(Hoeben et al., 2000). Briefly, E. coli P4:O32 (H37, β-
glucuronidase+, hemolysin−), maintained as a stock in
lyophilization medium at −20°C, was subcultured in
brain-heart-infusion broth (CM225; Oxoid, Nepean,
Ontario, Canada) at 37°C for 3 consecutive days and
subsequently washed 3 times with pyrogen-free PBS
and resuspended in PBS. Immediately before inocula-
tion, the suspension was diluted in pyrogen-free PBS
to a final concentration of 1 × 104 cfu/mL. On d 0, 30
min after morning milking (1.5 h after feeding), the
cows were inoculated in the left front and rear quarters
with a total volume of 10 mL, consisting of 1 mL of
inoculum and 9 mL of pyrogen-free saline solution
(NaCl 0.9%; Baxter N.V., Lessines, Belgium) per quar-
ter. All bacterial suspensions were infused into the teat
cistern using a sterile, pyrogen-free teat cannula
(length, 7 cm, i.d., 2 mm;Me.Ve.Mat, Deinze, Belgium).
Before challenge, the teat ends were disinfected with
70% ethanol containing 0.5% chlorhexidine. After infu-
sion, the bacterial suspension was thoroughly distrib-
uted into the udder cistern using a 30-s massage.
Following inoculation, a control sample of the inocu-
lum was diluted, plated out on Columbia agar with
5% sheep blood (Biokar Diagnostics, Beauvois, France),
and incubated for 24 h at 37°C to check for correct
inoculum preparation and adequate inoculum dose ad-
ministration at intramammary E. coli challenge.
Treatment Protocol
Carprofen, a powerful NSAID with unknown COX
selectivity in the bovine, was administered intrave-
nously into the jugular vein at PIH 9, when acute clini-
cal symptoms (rectal temperature >40°C, quarter swell-
ing, slightly abnormal milk appearance) were already
present. Carprofen (1.4 mg/kg, Rimadyl; kindly pro-
vided by Pfizer Animal Health, Sandwich, UK) was
administered according to BW (2.9 mL/100 kg). Control
animals received saline solution (0.9% NaCl; Baxter
N.V., Lessines, Belgium) according to BW (2.9 mL/
100 kg).
Sampling Procedure
Blood and milk samples were collected on d −4, d −1,
d 0, d +1, d +2, d +3, and d +6 relative to the day
of challenge. On the day of challenge, blood and milk
samples were collected at PIH 3, 6, 9, 12, 15, 18, and 21.
Blood samples were drawn aseptically from the exter-
nal jugular vein of each cow by venipuncture into evacu-
ated tubes. Foremilk (5 mL) was aseptically collected
for diagnostic bacteriology for major pathogens before
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inoculation and for quantification of the population of
E. coli (cfu) from PIH 3 onwards. Furthermore, milk
samples (100 mL) were collected manually, using a
method validated previously, for determination of SCC,
milk composition, and the preparation of milk whey
through centrifugation. All samples were kept on melt-
ing ice (1°C) during transport and at the laboratory
until analysis was performed or aliquots were prepared
for freezing (−20°C).
Clinical Examination
Classical clinical parameters were examined. Rectal
temperature (RT), HR, respiration rate, reticulorumen
motility, skin turgor, fecal appearance, appetite, gen-
eral attitude, BCS (Edmondson et al., 1989), and as-
pects of the mammary gland [abnormal milk, swelling,
temperature, pain, teat relaxation, and milk leakage
(Table 1) (Massart-Lee¨n et al., 1988)] were recorded at
each blood and milk sampling time.
Severity Determination and Clinical Severity Score
The severity of E. colimastitis was determined based
on quarter milk production in the uninfected quarters
at d +2 postinfusion. Animals with quartermilk produc-
tion in the uninfected quarters at d +2 higher than 50%
compared with their quarter milk production on d −1 in
the same quarters were scored as moderate responders,
whereas animals with a quarter milk production at d
+2 lower than 50% were considered severe responders
(Vandeputte-Van Messom et al., 1993; Dosogne et al.,
1997, 1999).
Clinical severity scoring was performed based on
Wenz et al. (2001) with slight modifications (Table 2)
(Vangroenweghe et al., 2004a,b). Clinical data (RT, skin
turgor, reticulorumen motility, and general attitude)
obtained from PIH 9 to 48 were scored, and based on
their total score, primiparous cows were classified into
mild, moderate, and severe responders.
SCC and Milk Composition
Somatic cell count was determined using a fluoro-
opto electronic method (Fossomatic 5000 cell counter;
Foss Electric, Hillerød, Denmark) by the Milk Control
Center (MCC, Lier, Belgium). Fat, protein, and lactose
concentrations (mg/mL) were determined using midin-
frared-photospectrometry (MilkoScan 4000; Foss
Electric).
Milk samples were centrifuged at 1000 × g (30 min,
4°C) for the determination of serum albumin (mg/dL),
sodium (Na+), chlorine (Cl−), and potassium (K+) concen-
tration (mmol/L). Fat was removed and samples of skim
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Table 1. Description of categorical parameters collected during examination of the mammary gland of
primiparous cows at all time points when blood and milk samples are collected. Temperature, quarter
swelling, pain, and teat relaxation were scored through manual palpation, whereas milk leakage and milk
appearance were assessed through visual inspection.
Parameter Score Description
Temperature 0 Normal
1 Abnormal: elevated to touch
Quarter swelling 0 Normal: no swelling, udder pliable and light in weight
1 Slight: udder less pliable with some firmness
2 Moderate: udder definitely firm and swollen
3 Severe: udder very hard and heavy
Pain 0 Absent
1 Present
Teat relaxation 0 Absent
1 Present
Milk leakage 0 Absent
1 Present
Milk appearance 0 Normal
1 Some flakes present
2 More flakes or clots present, slightly watery
3 Excessive flakes or clots, watery to bloody
milk were immediately frozen at −80°C until analysis.
Serumalbumin of thawed sampleswas quantifiedusing
a radial immunodiffusion kit (bovine low level albumin,
Bethyl VET-RID; Bethyl Laboratories, Montgomery,
TX). Briefly, 10 µL of milk whey was added to each well
and incubated at 20°C for 24 h before diameter of the
radial immunodiffusion reactionwas assessed. Squared
diameters (d2) were compared with a constructed stan-
dard curve of known amounts of serum albumin. Ion
concentration was analyzed using an ion-selective elec-
trode analyzer (Ilyte; Instrumentation Laboratories,
Milan, Italy).
Numbers of E. coli in Inoculated Quarters
The number of E. coli (cfu/mL) after experimental
inoculationwas determined by appropriate 10-fold dilu-
tions of each milk sample in PBS. Ten microliters of
each dilution was plated on Columbia agar with 5%
sheep blood (Biokar Diagnostics). All dilutions were
performed in duplicate. Colonies were counted after a
24-h incubation at 37°C. The colony count was con-
verted to cfu/mL based on the factor of dilution and
finally expressed as log10/mL for statistical analysis.
Packed Cell Volume and Blood Leukocyte Number
Blood packed cell volume (%) was determined in he-
matocrit capillaries (60 µL/75 mm; Hirschmann Labor-
gera¨te, Eberstadt, Germany) using a microhematocrit
centrifuge (Hawksley, London, UK). Blood leukocyte
number (log10/mL) was determined using an electronic
particle counter (Coulter Counter Z2; Coulter Electron-
ics Ltd., Luton, UK).
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Determination of IL-8
Milk IL-8 concentration was determined from undi-
luted whey samples assayed with a commercially avail-
able human IL-8ELISA kit (R&DSystems, Inc.,Minne-
apolis, MN). The antibody pairs used in this kit have
previously been shown to cross-react with bovine IL-8
(Shuster et al., 1996, 1997). Briefly, 100µL ofmilkwhey
sample was added to flat-bottomed microtiter plates,
precoated with mouse monoclonal anti-IL-8 antibodies,
and incubated for 1 h at 20°C. Following washing, poly-
clonal anti-IL-8 antibodies conjugated to horseradish
peroxidase were added and incubated (1 h, 20°C). The
substrate solution, tetramethylbenzidine (TMB;
Sigma), was freshly prepared and added to each well
following washing of the wells. After a 30-min incuba-
tion at room temperature, the reaction was stopped
with 2 N H2SO4. The optical density at 450 nm and a
correction wavelength of 550 nm were measured on
an automated microplate reader (BioKinetics Reader;
BioTek Instruments, Winooski, VT). Values expressed
in picograms per milliliter were extrapolated using lin-
ear regression from a standard curve of known amounts
of human IL-8.
Determination of C5a
Milk C5a was quantified by ELISA as previously de-
scribed (Rainard et al., 1998). Briefly, flat-bottomedmi-
crotiter plates (Immulon 1; Dynatech, Chantilly, VA)
were coatedwith 100µL of goat antimouse IgG (Jackson
Immunoresearch Laboratories, West Grove, PA) di-
luted to 2 µg/mL in 0.1M carbonate bicarbonate buffer
pH 9.6 for 1.5 h at 39°C. After each incubation, the
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Table 2. Severity estimation scheme, based on systemic disease signs, for the classification of heifers
following an experimental inoculation with Escherichia coli P4:O32 (Vangroenweghe et al., 2004a). Briefly,
the 4 parameters are scored, total score is calculated, and compared with respective ranges for classification
into mild, moderate, or severe disease.
Variable Criteria Score
Rectal temperature (°C) 37.80–39.25 0
39.30–39.80 1
<37.80 or >39.80 2
Skin turgor Regains normal shape in <5 s 0
Regains normal shape in >5 s 1
Rumen motility rate 3× per 2 min 0
(contractions/min) 1–2× per 2 min 1
0× per 2 min 2
General attitude Alert 0
(signs of depression) Lethargic 1
Depressed: unable to stand 2
Extremely sick: recumbent 3
Total score Mild disease 0–2
Moderate disease 3–5
Severe disease 6–8
plates were washed 5 times with PBS supplemented
with 0.1% (vol/vol) Tween 20.Unsaturated binding sites
were blocked with a solution of 0.5% (wt/vol) gelatin.
The sequence of incubation steps with 100 µL reagents
diluted with PBS-Tween plus 0.1% gelatin was as fol-
lows: (i) a 1/10,000 dilution of the anti-C5amousemono-
clonal antibody 6G4 for 1 h; (ii) 2-fold dilutions of puri-
fied C5adesArg for the calibration curve, or appropriate
dilutions of the milk whey sample under test, diluted
in PBS-Tween plus 0.1% gelatin containing 1 mM
EDTA for 1.5 h; (iii) a 1/5000 dilution of rabbit antibo-
vine C5a/C5 for 30min; (iv) a 1/10,000 dilution of horse-
radish peroxidase-conjugated goat antirabbit IgG
(Jackson Immunoresearch Laboratories) for 30 min; (v)
52 mM 2,2′-azido-di-(3-ethylbenzthiazoline-6-sulfonic
acid) (Sigma) in 0.1 M citrate buffer pH 4.2 with 7.5
mM hydrogen peroxide (Sigma). The absorbance at 415
nm was read after 30 min using an automated mi-
croplate reader (BioKinetics Reader; BioTek Instru-
ments). Values expressed in picograms per milliliter
were extrapolated using linear regression from a stan-
dard curve of known amounts of C5adesArg (Rainard et
al., 1998).
Determination of sCD14
A sandwich ELISAwas used to quantify sCD14 levels
in milk whey as described by Bannerman et al. (2003).
Briefly, flat-bottom 96-well plates were coated over-
night with 5 µg/mL of mouse antibovine CD14 mono-
clonal antibody (CAM36A; VMRD, Inc., Pullman, WA)
diluted in 0.05 M sodium carbonate-bicarbonate
(Sigma), pH 9.6 at 4°C. The plates were washed 4 times
with 0.05%Tween 20 diluted in 50mMTrizma-buffered
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saline (Sigma), pH 8.0, and subsequently blocked with
2% fish skin gelatin (Sigma) for 1 h at room tempera-
ture. Plates were washed and 100 µL of diluted whey
samples (1:10) were added to each well in duplicate.
Plates were incubated for 1 h at room temperature and
subsequently washed as above.Mouse antibovine CD14
antibody (MM61A clone; VMRD, Inc.) was conjugated
to horseradish peroxidase using a commercially avail-
able kit (EZ-Link Plus Activated Peroxidase kit; Pierce
Chemical Co., Rockford, IL) and used as the detection
antibody. This horseradish peroxidase-conjugated anti-
bovine CD14 antibody was diluted 1:1000 in Trizma-
buffered saline wash buffer containing 2% gelatin, and
100 µL of the resulting solution was added to each well.
Plates were incubated for 1 h at room temperature,
washed as above, and 100 µL of TMB substrate solution
(Pierce Chemical Co.) added to each well. The reaction
was stopped by the addition of 100 µL of 2 M H2SO4
and the absorbance read at 450 nm on a microplate
reader (Multiskan PLUS; Labsystems, Helsinki, Fin-
land). A background correction reading of 550 nm was
subtracted from the 450-nm absorbance readings. Val-
ues expressed inmicrograms per milliliter were extrap-
olated using linear regression from a standard curve of
known amounts of recombinant bovine sCD14 (Wang
et al., 2002).
Determination of LBP
Milk whey and plasma LBP levels were determined
with a commercially available LBP ELISA kit that
cross-reacts with bovine LBP (Cell Sciences, Inc., Nor-
wood, MA). Milk and plasma samples were diluted
1:400 and 1:1500, respectively, and assayed according
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to themanufacturer’s instructions. Briefly, dilutedmilk
whey or plasma samples were added to flat-bottomed
microtiter plates, precoatedwith solid bound antibodies
recognizing LBP of a wide variety of species, and incu-
bated at room temperature for 1 h. The plates were
washed 3 times and biotinylated LPS-tracer molecules
were added. Following incubation (1 h, 20°C) and 3
washings, streptavidin-peroxidase conjugated LBPwas
added (1 h, 20°C). After washing the nonbound conju-
gated LBP, freshly prepared substrate solution (TMB)
was added and the plates were incubated for 30 min
(20°C). The enzymatic reaction was stopped by addition
of citric acid. The optical density at 450 nmand a correc-
tion wavelength of 550 nm were measured on a mi-
croplate reader (Multiskan PLUS; Labsystems). The
concentration of LBP (expressed in µg/mL) was calcu-
lated by extrapolation using linear regression from a
standard curve of known amounts of human LBP.
Determination of PGE2
Milk whey and plasma PGE2 concentrations were
determined with a commercially available PGE2 com-
petitive ELISA kit (Neogen, Lexington, KY) according
to manufacturer’s instructions. Briefly, quarter milk
samples were filtered using a 70-µm cell strainer (Bec-
ton Dickinson; Erembodegem, Belgium) to discard cell
clusters. One milliliter of milk or plasma sample was
diluted with 1 mL of distilled water, and 1 mL of the
mixture was loaded on a 100-mg C18 column (Varian,
St.-Katelijne-Waver, Belgium) after conditioning with
2 mL of methanol followed by 2 mL of distilled water.
The column was subsequently washed with 1 mL of
each of the following substances: distilledwater,metha-
nol:distilledwater (30:70), and hexane. The columnwas
centrifuged at 3200 × g for 3 min to remove any trace
of hexane. Finally, eicosanoids were eluted from the
C18 columnwith 1mL ofmethanol. The collected eluate
was evaporated to dryness under a stream of nitrogen.
Dried samples were reconstituted in an appropriate
volume of assay buffer.
Fifty microliters of the sample was added to the flat-
bottomed microtiter plates, precoated with mouse
monoclonal antibodies against PGE2. Subsequently, 50
µL of diluted enzyme conjugate was added and the mix-
ture was incubated at 20°C for 1 h. After the plates
were washed, 150 µL of substrate solution (TMB) was
added and incubated (15min, 20°C). The optical density
at 630 nm and a correction wavelength at 490 nm were
measured on a microplate reader (Multiskan PLUS;
Labsystems). The concentration of PGE2 (expressed in
pg/mL) was calculated by extrapolation using linear
regression from a standard curve of known amounts
of PGE2.
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Determination of Thromboxane B2
Milk and plasma thromboxane B2 (TXB2) concentra-
tions were determined with a commercially available
TXB2 competitive ELISA kit (Neogen, Lexington, KY)
according tomanufacturer’s instructions. Sampleswere
prepared for analysis as described above for PGE2.
Briefly, 50 µL of the sample was added to the flat-
bottomed microtiter plates, and precoated with rabbit
monoclonal antibodies against TXB2. After addition of
50 µL of diluted enzyme conjugate, the mixture was
incubated at 20°C for 1 h. Following washing, 150 µL of
substrate (TMB) was added (15 min, 20°C). The optical
density at 630 nm and a correction wavelength at 490
nm were measured on a microplate reader (Multiskan
PLUS; Labsystems). The concentration of TXB2 (ex-
pressed in pg/mL) was calculated by extrapolation us-
ing linear regression from a standard curve of known
amounts of TXB2.
Statistical Analyses
To compare the 2 treatment groups with respect to
the various parameters analyzed in blood and milk, a
mixed model was used with cow as random effect, and
treatment, time, and their interaction as categorical
fixed effects. Furthermore, the 2 treatment groups were
compared at PIH 12 for all analyzed parameters, and
some determined parameters were tested at posttreat-
ment intervals PIH 12 to 18 (RT, HR, blood leukocyte
number, and packed cell volume), PIH 12 to 48 (IL-8,
C5a, sCD14, LBP, PGE2, and TXB2) and PIH 12 to 72
(SCC, cfu, lactose, Na+, K+, Cl−, and serum albumin),
respectively, for significant differences between both
treatment groups. Bonferroni’s multiple comparisons
procedure with an overall type I error equal to 5% was
used to adjust for multiple comparisons. Quarter milk
production in both infected anduninfected quarterswas
tested for significant differences between treatments at
d +1 and the interval d +1 − d +3. The effect of treatment
on the local aspects of the mammary gland and the
clinical severity score was tested by the Wilcoxon rank
sum test.
RESULTS
Local and Systemic Inflammatory Response
Following intramammaryE. coli inoculation, RT rap-
idly increased from PIH 9 onward, to reach a maximum
at PIH12 in the saline-treated group. Carprofen admin-
istration at PIH 9 immediately reduced RT (P < 0.0001)
at 3 (PIH 12) and 6 h (PIH 15) posttreatment, and RT
normalized at PIH 15 (6 h posttreatment). No relapses
of RT increase were observed in the carprofen-treated
VANGROENWEGHE ET AL.2368
group, whereas in the saline-treated group, RT in-
creased above 39°C again at PIH 24 (Figure 1a).
Heart rate followed almost identical kinetics as de-
scribed for RT. In the carprofen-treated group, HR was
(P < 0.05) lower at PIH 12 and 15. From 6 h posttreat-
ment onward, HR in the carprofen-treated animals re-
mained lower, although not significant, until the end
of the observation period (Figure 1b). Respiration rate
followed identical kinetics as RT and HR (results not
shown).
Carprofen treatment following intramammaryE. coli
inoculation has a beneficial effect on the duration of
reticulorumen motility depression. Although reticulo-
rumen motility was equally depressed in both treat-
ment groups at PIH 9 (time of treatment), the depres-
sion disappeared following carprofen treatment (P <
0.01), whereas in the saline-treated group, depression
of reticulorumen motility reached its maximum at PIH
12 (Figure 1c).
Local clinical symptoms at the level of the mammary
gland were also assessed during clinical examination.
Local swelling appeared at PIH 6 and reached its maxi-
mum at PIH 12 in both treatment groups. In the carpro-
fen-treated animals, quarter swelling decreased from
PIH 18 and normal quarter consistency was present at
PIH 144. Quarter swelling decreased more slowly in
control animals, although normal quarter consistency
at palpation was also reached by PIH 144. Maximal
quarter swelling score was lower (P < 0.05) in the car-
profen-treated animals. Milk appearance, quarter milk
leakage scores, andmaximummilk leakage scores were
significantly (P < 0.05) higher in the carprofen-treated
group at PIH 12. Quarter pain and temperature did
not differ between the treatment groups (results not
shown).
Clinical Severity Scoring
Based on the clinical severity scoring system by Van-
groenweghe et al. (2004a), clinical scores increased to
a maximum in both treatment groups at PIH 12. The
clinical severity score in the carprofen-treated group
decreased more rapidly from 6 h posttreatment on-
wards. At PIH 15, clinical severity score was lower (P
< 0.01) in the carprofen-treated group compared with
the saline-treated group.
At PIH 9, the time of treatment, approximately equal
numbers of animals in both treatment groups displayed
a mild and moderate response. Following carprofen ad-
ministration, all animals (n = 12) responded mildly
(score 0 to 2), whereas in the saline-treated group, 6
animals reacted with a moderate response (score 3 to
5), and only 7 animals had a mild response. By 6 h
posttreatment, 10 animals in the carprofen-treated
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Figure 1.Rectal temperature (RT) (A), heart rate (HR) (B), reticu-
lorumen motility (contractions per 2 min) (C), packed cell volume
(D), blood leukocyte count (BLC) (E), plasma LPS-binding protein
(LBP) (F), plasma prostaglandin E2 (G), and plasma thromboxane
B2 (TXB2) (H) from postinfusion hour (PIH) 0 until PIH 144 from
primiparous cows infused with 1 × 104 cfu of Escherichia coli P4:O32
and treated at PIH 9 (vertical dashed line) with carprofen (solid line;
n = 12) or saline (dotted line; n = 13). Data are means (± SEM).
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Table 3. Classification of heifers into mild/moderate/severe responders based on the severity estimation
score at postinfusion hour (PIH) 9, 12, and 15. The numbers in the body of the table represent the number
of animals having the specified score at the respective PIH. In the present study, the total score did not
exceed 5, meaning that no severe responses were observed throughout the entire experimental study period.
Clinical score
Mild response Moderate response Severe response
PIH Group 0 1 2 3 4 5 6 7 8
9 Saline 2 1 4 6 0 0 0 0 0
Carprofen 0 0 7 5 0 0 0 0 0
12 Saline 0 0 7 4 2 0 0 0 0
Carprofen 2 6 4 0 0 0 0 0 0
15 Saline 3 4 5 1 0 0 0 0 0
Carprofen 10 1 0 1 0 0 0 0 0
group had a score of 0, whereas in the saline-treated
group, only 3 animals had a score of 0; the others scored
1 (n = 4), 2 (n = 5), or 3 (n = 1) (Table 3). At the subse-
quent time points, the clinical severity score in both
groups seemed to normalize with only a slight flare-up
of 3 animals (score 2) in the saline-treated group at
PIH 24.
Quarter Milk Production
Milk production in the infected quarters decreased
equally on d 0, the day of intramammary E. coli chal-
lenge, in both treatment groups. In this study, carprofen
treatment did not significantly affect the recovery of
milk production in the infected quarters compared with
saline treatment (Figure 2a). In the uninfected control
quarters, no significant differences in milk production
were observed throughout the entire study period (Fig-
ure 2b).
As expected, none of the animals in either treatment
group reacted as severe responder, based on the quarter
milk production of the uninfected quarters at d +2 com-
pared with the quarter milk production in these quar-
ters at d −1 (Vandeputte-VanMessom et al., 1993). This
is in agreement with recent findings that primiparous
cows react moderately following intramammary E. coli
challenge (Vangroenweghe et al., 2004a,b).
Intramammary Growth of Inoculated E. coli, SCC,
Packed Cell Volume, and Blood Leukocyte Count
The number of E. coli increased to plateau [4.07 and
3.89 log10(cfu)/mL] at PIH 6. This plateau was followed
by a slow, but steady decrease in both treatment groups.
No significant differences in the number of E. coli (PIH
12 to 48) were observed throughout the experimental
period (Figure 3a). Somatic cell count increased during
the early phase of inflammation, although SCC only
exceeded 1 × 106 cells/mL at PIH 9 in both treatment
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groups. Following treatment at PIH 9, no significant
differences in SCC (PIH 12 to 48) were observed
throughout the experimental period (Figure 3b).
A decrease in blood leukocyte number occurred from
PIH 9 onwards, and nadir blood leukocyte number was
reached at PIH 12. This was followed by a steady in-
crease to preinfection levels at PIH24 (Figure 1e). Blood
leukocyte count did not differ significantly between both
treatment groups during the period immediately follow-
ing intravenous carprofen treatment (PIH 12 to 18).
Milk Composition
Lactose, serum albumin, sodium, potassium, and
chlorine are indicators of changes in milk composition
following mastitis (Burvenich, 1983). Following E. coli
challenge, lactose concentration started to decrease at
PIH 9, reaching nadir at PIH 12 (3 h posttreatment)
in both treatment groups. No significant differences
(PIH 12 to 48) in lactose concentration were observed
following carprofen treatment (Figure 3c). Maximal
concentrations of serum albumin in milk were reached
at PIH 15. In the interval PIH 12 to 48, serum albumin
concentration showed an interaction between time and
treatment (P = 0.013), meaning that serum albumin
kinetics were different between groups. At PIH 21, car-
profen-treated animals had lower concentrations of se-
rum albumin in the milk of the affected quarters (P =
0.0099; Figure 3d).
Concentration of Na+ was lower in the carprofen-
treated animals at PIH 21 (P = 0.005) and PIH 24 (P =
0.007), whereas the K+ concentration was higher in the
carprofen-treated animals at PIH 21 (P = 0.002) and
PIH 24 (P = 0.005) (Figure 3e and f). The Cl− concentra-
tion was lower in the carprofen-treated group than the
saline-treated group at PIH 21 (P = 0.013) (Figure 3g).
Milk IL-8, C5a, and sCD14
Before challenge, IL-8 was very low (1.66 ± 0.23 and
2.11 ± 0.35 pg/mL in the saline and carprofen-treated
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Figure 2. Quarter milk production (QMP) in the infected (A) and
uninfected (B) quarters from PIH −168 until PIH 144 from primipa-
rous cows infused with 1 × 104 cfu of Escherichia coli P4:O32 and
treated at PIH 9 with carprofen (solid line; n = 12) or saline (dotted
line; n = 13). Data are means (± SEM).
groups, respectively) in the quarters that were to be
infusedwithE. coli. Until PIH 9 (the time of treatment),
IL-8 kinetics did not differ between both treatment
groups. Peak concentrations (471 ± 50 and 389 ± 61 pg/
mL for the saline- and carprofen-treated group, respec-
tively) were reached in the period PIH 12 to 15. No
significant differences between treatments could be ob-
served throughout the study period (Figure 4a).
The complement component C5a had similar kinetics
in both treatment groups until PIH 18, 9 h posttreat-
ment. From PIH 21, C5a concentration decreased in
the treated animals, whereas animals in the saline-
treated groups reached peak C5a levels at PIH 24, fol-
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Figure 3. Colony-forming units of Escherichia coli (A), SCC (B),
lactose (C), serum albumin (D), sodium (E), potassium (F), and chlo-
rine (G) in the infected quarters from postinfusion hour (PIH) 0 until
PIH 144 from primiparous cows infused with 1 × 104 cfu of E. coli
P4:O32 and treated at PIH 9 (dashed vertical line) with carprofen
(solid line; n = 12) or saline (dotted line; n = 13). Data are means
(± SEM).
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Figure 4. Concentrations of IL-8 (A), complement component 5a
(B), soluble CD14 (C), LPS-binding protein (D), prostaglandin E2 (E),
and thromboxane B2 (F) in the infected quarters from postinfusion
hour (PIH) 0 until PIH 144 from primiparous cows infused with 1 ×
104 cfu of Escherichia coli P4:O32 and treated at PIH 9 (dashed
vertical line) with carprofen (solid line; n = 12) or saline (dotted line;
n = 13). Data are means (± SEM).
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lowed by a decrease at PIH 48, but no significant differ-
ences between the 2 groups were observed. At PIH 72,
C5a levels in both groups reached similar values (Fig-
ure 4b).
Before challenge, sCD14 concentration in mammary
quarters (7.33 ± 1.72 and 3.77 ± 0.70 µg/mL in saline-
and carprofen-treated animals, respectively) was in a
range similar to that reported by Lee et al. (2003a) for
early lactating uninfected glands (5.46 to 6.90 µg/mL).
In both treatment groups, a first peak was observed at
PIH 12 (11 ± 2 and 13 ± 2 µg/mL, respectively) followed
by a second, higher peak at PIH 24 (27 ± 4 and 31 ± 6 µg/
mL). Following peak concentrations, sCD14 decreased
fromPIH 48 to reach normal preinfection values by PIH
144. No significant differences in sCD14 concentrations
were observed throughout the entire experimental pe-
riod (Figure 4c).
Plasma and Milk LBP
It was shown previously (Bannerman et al., 2003)
that elevated levels of sCD14were associatedwith simi-
lar increases in milk LBP, thereby providing an envi-
ronment for optimal host recognition of LPS, originat-
ing from inoculatedE. coli bacteria. In addition to quan-
tifying milk LBP to assess possible effects of carprofen
treatment on the levels of LBP in the infected quarters,
plasma LBP was assayed, as it is known that hepatic
synthesis of this protein increases during the acute-
phase response, mainly due to hepatic cell stimulation
by IL-1β and IL-6 (Tobias et al., 1999), which could be
influenced byNSAID treatment through the intermedi-
ate eicosanoid products, PGE2 and TXB2. Under basal
conditions, LBP was detected in bovine blood at concen-
trations of 71.3 ± 10.9 and 98.3 ± 16.2 µg/mL for saline-
and carprofen-treated animals, respectively; whereas
the concentration of LBP in milk was lower, at 18.1 ±
2.3 and 23.7 ± 2.2 µg/mL for the 2 groups, respectively.
Plasma LBP increased from PIH 15 onwards to reach
maximal values at PIH 24 (162 ± 10 and 167 ± 14 µg/mL
for saline- and carprofen-treated animals, respectively).
Thereafter, concentrations of plasma LBP declined to
reach preinfection levels at PIH144 (Figure 1f). In quar-
ters inoculated with E. coli, milk LBP was elevated
from PIH 9 onwards, with maxima (58 ± 1 and 61 ± 1
µg/mL in saline- and carprofen-treated animals, respec-
tively) at PIH 21. From PIH 48 on, milk LBP concentra-
tions declined (Figure 4d). Milk LBP was significantly
lower in the carprofen-treated than saline-treated ani-
mals at PIH 12 (P = 0.0001).
Plasma and Milk PGE2 and TXB2
Plasma PGE2 concentration was 429.2 ± 25.2 pg/mL
at the time of inoculation in both treatment groups.
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Prostaglandin E2 started to decrease in plasma as early
as PIH 9 and reached nadir at PIH 15 in both treatment
groups. Plasma PGE2 concentrations did not differ sig-
nificantly between carprofen-treated and saline-treated
animals (Figure 1g). Thromboxane B2 concentration in
plasma was as high as 180.4 ± 26.5 pg/mL at the time
of infection. Throughout the inflammatory episode, no
significant difference between TXB2 kinetics in the
treatment groups was observed (Figure 1h).
In milk, PGE2 concentration was lower than in
plasma and was 334.8 ± 21.1 pg/mL at the time of
intramammary inoculation. Prostaglandin E2 subse-
quently increased fromPIH 9 onward in both treatment
groups. No significant difference in milk PGE2 concen-
tration was observed between the carprofen- and the
saline-treated animals (Figure 4e). Initial milk TXB2
concentrations (84.3 ± 5.1 pg/mL) were markedly lower
than concentrations observed in plasma. Thromboxane
B2 increases occurred at PIH 9, which was also the
maximal concentration, in the carprofen-treated ani-
mals. In saline-treated animals, TXB2 further increased
and reached its maximum at PIH 15. The milk TXB2
concentrations continued to be higher in the saline-
treated groups comparedwith the carprofen-treated an-
imals until PIH 72, but the difference was not sig-
nificant.
DISCUSSION
The aim of the present study was to evaluate the
potential modulatory effects of carprofen treatment on
a moderate inflammatory reaction following E. coli
challenge. Carprofen is a PG synthetase inhibitor via
COX inhibition. Therefore, the study design included
carprofen administration following the appearance of
initial clinical symptoms (Shpigel et al., 1994) and in-
flammatory dynamics of the moderate inflammatory
model used (Vangroenweghe et al., 2004a,b). It is
known that pretreatment is more effective in inhibiting
the inducible COX-2 enzyme (Burvenich, 1985; Burven-
ich et al., 1989); however, from a practical point of view,
the earliest occasion at which field cases of clinical E.
coli mastitis can be diagnosed and subsequently
treated, occurs at the milking following the infection of
the mammary quarter (Shpigel et al., 1994, 1996). The
first clinical signs (RT > 40°C, quarter swelling, slightly
abnormal milk appearance) in the present experimen-
tal model, using a 1 × 104 cfu inoculum dose, appeared
around PIH 9. Therefore, the choice for a carprofen
administration at PIH 9 was considered most suitable,
as clinical signs (RT = 40.6 ± 0.17°C) would be present
at that time, althoughmaximal RT was not yet reached
(Vangroenweghe et al., 2004a,b).
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In the present study, the same strain and high inocu-
lum dose of E. coli was used to induce a moderate in-
flammatory reaction in primiparous cows as described
previously (Vangroenweghe et al., 2004a,b). The clinical
course and changes in different laboratory parameters
following intramammaryE. coli challenge in the control
animals were similar to animals receiving the same
dose (1 × 104 cfu) in previous experiments (Vangroen-
weghe et al., 2004a,b). Carprofen-treated animals dem-
onstrated an immediate and significant decrease in RT
at 3 h posttreatment, whereas pyrexia continued in the
control animals with a peak fever at PIH 12. Single-
dose carprofen administration in the present study re-
sulted in a more pronounced and prolonged antipyretic
effect compared with meloxicam treatment in an E.
coli endotoxin model (Banting et al., 2000), where peak
fever was reached at 2 h posttreatment in both groups.
Reticulorumen motility was equally depressed in both
treatment groups at the time of carprofen administra-
tion. However, 3 h posttreatment, reticulorumen motil-
ity in the carprofen-treated animals returned to normal,
whereas a maximal depression was reached in the con-
trol group at PIH 12. A similar effect on reticulorumen
motility was observed with meloxicam treatment in the
E. coli endotoxin model (Banting et al., 2000).
Improvement of local clinical signs at the level of
the affectedmammary quarters by carprofen treatment
was limited to swelling and milk appearance. These
observations are in accordance with Anderson et al.
(1986), who reported significant improvement of quar-
ter temperature, edema, pain, and size following fluni-
xin meglumine treatment of cows suffering from endo-
toxin-induced mastitis. However, the administration of
flunixin meglumine in that study was performed much
earlier (PIH 2) than in our study, where carprofen was
only administered at appearance of the first clinical
symptoms, such as an elevated RT (>40°C), quarter
swelling, and slightly abnormal milk appearance.
Dehydration is often assessed during acute coliform
mastitis as an easy tool to judge clinical severity. The
assessment of dehydration can be performed by skin
turgor estimation. In the present study, no difference
in skin turgor could be observed throughout the study
period. This could have been expected based on the
mild to moderate responses usually obtained using this
experimental infection model. Packed cell volume did
not differ among treatments throughout the study
either.
Clinical scores, combining several clinical parame-
ters, have been described (Wenz et al., 2001; Friton
et al., 2002; Vangroenweghe et al., 2004a). Using the
clinical severity score described by Vangroenweghe et
al. (2004a), carprofen-treated animals had a signifi-
cantly lower clinical score at PIH 12 and 15 compared
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with the saline-treated group (Table 3). Although, as
expected from previous trials, all animals in both
groups respondedmildly to moderately followingE. coli
challenge, the carprofen-treated animals generally
showed a lower clinical severity score within 3 h of
NSAID administration. This was mainly due to the
restoration of reticulorumen motility and antipyretic
activity of the NSAID.
Quarter inflammation was associated with a tempo-
rary loss of milk production, combined with secretion
of abnormal milk from the infected glands. Maximal
depression in milk production in the infected and unin-
fected quarters occurred on the day of challenge (d 0),
andwas followed by a rapid recovery during subsequent
days. Carprofen treatment exerted no significant bene-
ficial effect onmilk yield in the infected quarters follow-
ing intramammaryE. coli challenge. The absence of any
significant effect of carprofen on the milk production in
the uninfected right quarters may be attributed to the
moderate inflammatory signs of the present mastitis
model.
In the present study, no significant effect of carprofen
treatment on bacterial elimination occurred, which
could be expected as carprofen treatment was adminis-
tered alone and not as an adjunctive therapy to intra-
mammary or systemic antibiotics. Fluoroquinolones are
known to enhance bacterial clearance during experi-
mentally induced E. coli mastitis (Monfardini et al.,
1999). Rantala et al. (2002) reported a more rapid de-
cline in bacterial number in the infected quarters fol-
lowing combined flunixin meglumine and fluoroquino-
lone treatment, which could probably be attributed to
the fluoroquinolone treatment and not the adjunctive
NSAID therapy.
The leukocyte influx into the infected glands follow-
ing E. coli challenge was not significantly affected by
carprofen treatment. This could assure continuing ele-
vated levels of PMNL at the site of infection, facilitating
their local role in combating E. coli bacteria present in
the infected glands. This observation is in accordance
with previous results obtained using flurbiprofen in ex-
perimentally induced LPSmastitis in goats (Burvenich,
1985; Burvenich et al., 1989). Comparable results were
obtained following ibuprofen treatment at 2 h postinfu-
sion of endotoxin (DeGraves and Anderson, 1993). Al-
though the dose of carprofen (1.4mg/kg of BW) adminis-
tered intravenously in the present study was twice as
high as the dose (0.7 mg/kg of BW) used by Lohuis
et al. (1991), edema and leukocyte infiltration in the
affected glands could not be prevented. Nevertheless,
the applied treatmentwas potent enough to reduce eico-
sanoid generation in the affected mammary glands in
the carprofen-treated animals. In the blood, similar ki-
netics could be observed in blood leukocyte number be-
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tween both treatment groups. Nadir blood leukocyte
number was reached at PIH 12, 3 h posttreatment in
both treatment groups, andwas followed by progressive
recovery of blood leukocyte number to preinfection lev-
els by PIH 24.
Lactose, serum albumin, sodium, potassium, and
chlorine concentrations in milk of the infected quarters
are often determined to assess the severity andduration
of the intramammary inflammation. Serum albumin
and all ions (Na+, K+, and Cl−) showed similar kinetics,
with a significant interaction between time and treat-
ment (not significant for Cl−) from 12 h posttreatment
(PIH 21) onward in the carprofen-treated animals.
These results indicate that carprofen induces a more
rapid recovery of normal milk composition in animals
intramammarily challengedwithE. coli. Previous stud-
ies using ibuprofen in an endotoxin model were unable
to demonstrate any effect on milk composition (De-
Graves and Anderson, 1993). The terminal half-life of
carprofen in healthy cows has been calculated to be 30.7
h, which is shorter than the half-life of phenylbutazone
(31.2 to 82.1 h), but considerably longer than flunixin
meglumine (8.1 h) (Lohuis et al., 1991). Therefore, it
is not surprising that a single dose of carprofen had
prolonged beneficial effects on clinical parameters com-
pared with the control group.
Following intramammary E. coli challenge, signifi-
cant increases in PGE2 (Zia et al., 1987; Peter et al.,
1990) and TXB2 (Anderson et al., 1985, 1986; Zia et al.,
1987) have been observed in milk. Moreover, a signifi-
cant effect of flunixin meglumine administration on
TXB2 concentrations was reported (Anderson et al.,
1986). Even in the uninfected quarters, a slight increase
in PGF2α and TXB2 concentration was reported (Ander-
son et al., 1985), although this increase disappeared
more rapidly than in the infected quarters. Following
flunixinmeglumine treatment, TXB2 concentrations re-
mained at baseline levels, whereas in the saline-treated
animals, a pronounced peak value was observed at PIH
8 in the endotoxin-challenged animals (Anderson et al.,
1986). Similar trends were observed in the present
study, but did not reach significance.
Although the effect of NSAID on eicosanoid produc-
tion following inflammation is well documented in the
literature (Anderson et al., 1986), no reports are avail-
able on the possible effect on other immunological in-
flammatory parameters, such as the chemotactic agents
IL-8 and C5a or the early innate immune molecules
sCD14 and LBP. Interleukin-8 kinetics in the present
study were similar with previous reports using the
same inoculum dose (Vangroenweghe et al., 2004b). Lo-
cal IL-8 production started at PIH 6, although major
increases only occurred from PIH 9 onwards. Because
IL-8 is a well-known chemotactic agent, it is obvious
VANGROENWEGHE ET AL.2374
from these results that the initial leukocyte influx into
the infected quarters, which occurred around PIH 9,
was not affected by the decline of IL-8 occurring much
later during inflammation. The appearance and evolu-
tion of C5a concentrations in the affected quarters did
not differ between both groups until PIH 21 (12 h post-
treatment). In the control group, C5a increased until
maximal values at PIH 24, which is 6 h later than
previously observed (Vangroenweghe et al., 2004b). The
marked difference in the onset of carprofen effects on
chemotactic agents IL-8 and C5a could be explained by
the location of mediator production. Interleukin-8 is
directly produced by the epithelial cells in the mam-
mary gland (Baggiolini and Clark-Lewis, 1992; Barber
and Yang, 1998), whereas the bulk of C5a precursors
are obtained from the blood through leakage of the
disintegrated blood-milk barrier (Rainard et al., 1998;
Rainard, 2003).
In accordance with previous reports (Bannerman et
al., 2003; Vangroenweghe et al., 2004b), the increases
in milk LBP paralleled increments in sCD14 levels.
From a host perspective, the simultaneous increase in
both LBP and sCD14 levels would be expected to be
advantageous as both molecules act in concert to facili-
tate activation of host defense mechanisms by pre-
senting LPS, released during bacterial growth and
death, to the transmembrane LPS receptor, TLR-4
(Bannerman and Goldblum, 2003). Carprofen treat-
ment did not significantly affect either parameter.
The present study showed that carprofen treatment
following experimental E. coli challenge in a moderate
inflammation model with primiparous cows has small
modulatory effects on some of the inflammatory mark-
ers, but obvious effects on some of the key clinical mark-
ers, such as RT and reticulorumen motility. Adminis-
tration of carprofen at PIH 9, when first clinical signs
occurred, showed beneficial effects on general clinical
condition, recovery of milk composition, and reduced
production of eicosanoids. Mediators of early innate im-
mune response, IL-8, C5a, sC14 and LBP, were not
significantly affected by NSAID treatment.
CONCLUSIONS
The inflammatory model using primiparous cows
during the periparturient period is a moderate state
of inflammation, necessary to eliminate the invading
pathogens from the affected mammary quarters. Car-
profen treatment was administered late during the
acute-phase reaction, when first clinical signs ap-
peared, and had modulatory effects on clinical and im-
munological parameters. The main modulatory poten-
tial occurred at the level of improved clinical condition,
mainly due to the antipyretic effects and the ability
Journal of Dairy Science Vol. 88, No. 7, 2005
of carprofen to improve reticulorumen motility. Milk
composition was significantly affected by carprofen
treatment at PIH 21 and 24, but no further effects on
milk composition occurred and milk production was not
significantly affected. Carprofen treatment did not sig-
nificantly affect PGE2 and TXB2 in plasma but reduced
their concentrations inmilk.Moreover, carprofen treat-
ment did not result in a significant decrease of chemo-
tactic inflammatory mediators, IL-8 and C5a, and early
innate immune molecules, such as sCD14 and LBP.
Major immunomodulatory effects from NSAID admin-
istration were therefore not observed in this model,
although a larger study might confirm some apparent
trends in the results presently obtained.
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